COVID-19 Induced Coagulopathy (CIC): Thrombotic Manifestations of Viral Infection.

Swati Sharma, Aastha Mishra, Zahid Ashraf
{"title":"COVID-19 Induced Coagulopathy (CIC): Thrombotic Manifestations of Viral Infection.","authors":"Swati Sharma,&nbsp;Aastha Mishra,&nbsp;Zahid Ashraf","doi":"10.1055/s-0042-1744185","DOIUrl":null,"url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and may result in an overactive coagulative system, thereby resulting in serious cardiovascular consequences in critically affected patients. The respiratory tract is a primary target for COVID-19 infection, which is manifested as acute lung injury in the most severe form of the viral infection, leading to respiratory failure. A proportion of infected patients may progress to serious systemic disease including dysfunction of multiple organs, acute respiratory distress syndrome (ARDS), and coagulation abnormalities, all of which are associated with increased mortality, additionally depending on age and compromised immunity. Coagulation abnormalities associated with COVID-19 mimic other systemic coagulopathies otherwise involved in other severe infections, such as disseminated intravascular coagulation (DIC) and may be termed COVID-19 induced coagulopathy (CIC). There is substantial evidence that patients with severe COVID-19 exhibiting CIC can develop venous and arterial thromboembolic complications. In the initial stages of CIC, significant elevation of D-dimer and fibrin/fibrinogen degradation products is observed. Alteration in prothrombin time, activated partial thromboplastin time, and platelet counts are less common in the early phase of the disease. In patients admitted to intensive care units (ICUs), coagulation test screening involving the measurement of D-dimer and fibrinogen levels, has been recommended. Prior established protocols for thromboembolic prophylaxis are also followed for CIC, including the use of heparin and other standard supportive care measures. In the present review, we summarize the characteristics of CIC and its implications for thrombosis, clinical findings of coagulation parameters in SARS-CoV-2 infected patients with incidences of thromboembolic events and plausible therapeutic measures.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":"6 1","pages":"e70-e79"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913175/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TH Open: Companion Journal to Thrombosis and Haemostasis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1744185","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and may result in an overactive coagulative system, thereby resulting in serious cardiovascular consequences in critically affected patients. The respiratory tract is a primary target for COVID-19 infection, which is manifested as acute lung injury in the most severe form of the viral infection, leading to respiratory failure. A proportion of infected patients may progress to serious systemic disease including dysfunction of multiple organs, acute respiratory distress syndrome (ARDS), and coagulation abnormalities, all of which are associated with increased mortality, additionally depending on age and compromised immunity. Coagulation abnormalities associated with COVID-19 mimic other systemic coagulopathies otherwise involved in other severe infections, such as disseminated intravascular coagulation (DIC) and may be termed COVID-19 induced coagulopathy (CIC). There is substantial evidence that patients with severe COVID-19 exhibiting CIC can develop venous and arterial thromboembolic complications. In the initial stages of CIC, significant elevation of D-dimer and fibrin/fibrinogen degradation products is observed. Alteration in prothrombin time, activated partial thromboplastin time, and platelet counts are less common in the early phase of the disease. In patients admitted to intensive care units (ICUs), coagulation test screening involving the measurement of D-dimer and fibrinogen levels, has been recommended. Prior established protocols for thromboembolic prophylaxis are also followed for CIC, including the use of heparin and other standard supportive care measures. In the present review, we summarize the characteristics of CIC and its implications for thrombosis, clinical findings of coagulation parameters in SARS-CoV-2 infected patients with incidences of thromboembolic events and plausible therapeutic measures.

Abstract Image

Abstract Image

Abstract Image

COVID-19诱导凝血功能障碍(CIC):病毒感染的血栓性表现。
2019冠状病毒病(COVID-19)由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引起,可导致凝血系统过度活跃,从而对危重患者造成严重的心血管后果。呼吸道是COVID-19感染的主要目标,最严重的病毒感染形式表现为急性肺损伤,导致呼吸衰竭。一部分感染患者可能发展为严重的全身性疾病,包括多器官功能障碍、急性呼吸窘迫综合征(ARDS)和凝血功能异常,所有这些都与死亡率增加有关,此外还取决于年龄和免疫力受损。与COVID-19相关的凝血异常类似于其他系统性凝血病,否则会涉及其他严重感染,如弥散性血管内凝血(DIC),可称为COVID-19诱导的凝血病(CIC)。有大量证据表明,出现CIC的重症COVID-19患者可发生静脉和动脉血栓栓塞并发症。在CIC的初始阶段,观察到d -二聚体和纤维蛋白/纤维蛋白原降解产物的显著升高。凝血酶原时间、活化的部分凝血活酶时间和血小板计数的改变在疾病早期不太常见。对于入住重症监护病房(icu)的患者,建议进行凝血试验筛查,包括测量d -二聚体和纤维蛋白原水平。CIC也遵循先前建立的血栓栓塞预防方案,包括使用肝素和其他标准支持治疗措施。在本文中,我们总结了CIC的特点及其对SARS-CoV-2感染患者血栓形成的影响、凝血参数的临床表现、血栓栓塞事件的发生率和合理的治疗措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信